November 28, 2005
For Immediate Release
Embolic Protection Gaining Acceptance -- November 2005 MedMarkets
FOOTHILL RANCH, CA — Applications in cardiology and neurointerventional indications in embolic protection represent a nearly $1 billion unrealized market opportunity. With a U.S. prevalence in stroke of over 5 million and an annual incidence of 700,000, combined with recent or pending approvals, much of this market is about to be realized, representing a windfall for competitors in the field. The current status of trials and product developments are covered in the November 2005 issue of MedMarkets, from MedMarket Diligence.
"Trials recently completed or underway are demonstrating the requisite outcomes," says Patrick Driscoll, publisher of MedMarkets. "As a result, recent approvals (e.g., Abbott Vascular Devices' Emboshield) are setting the stage for big growth in embolic protection over the next several years."
The November 2005 edition of MedMarkets details these developments and field of competitors in embolic protection: Abbott Vascular Devices, Boston Scientific, Cordis, ev3, Guidant, Invatec, Kensey Nash, Medtronic, MIV Therapeutics, and St. Jude Medical.
MedMarket Diligence provides tactical decision-making solutions on medical
technology to the medical products and investment industries. The company
MedMarkets newsletter, a monthly analysis of the market implications of new
medical technologies, and dedicated reports on technology markets. For
additional details, contact Patrick Driscoll at
email or call
949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.